Form 4: ALX Oncology Holdings Inc. Executive Jaume Pons Reports Stock Sale to Cover Tax Obligations

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., sold 1,326 shares of common stock on February 19, 2025, to satisfy tax obligations related to vesting restricted stock units.

Summary

• Jaume Pons, President & CSO of ALX Oncology Holdings Inc., reported a transaction involving the sale of company stock.
• On February 19, 2025, Pons sold 1,326 shares of common stock at a weighted average price of $1.1502 per share.
• The sale was executed to cover tax obligations associated with the vesting of restricted stock units.
• Following the transaction, Pons directly owns 579,388 shares of ALX Oncology Holdings Inc.
• Pons has granted power of attorney to Jason Lettmann, Chris Byrd, and Shelly Pinto to handle SEC filings related to company stock transactions.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing detailing an executive's stock sale for tax purposes. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The transaction is a routine sale to cover tax obligations related to vested stock units, which is a common practice among executives.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which is common in the biotechnology industry. Executives often sell shares to cover tax obligations related to stock-based compensation.

Stakeholder Impact

• The stock sale by an executive could have a minor impact on shareholder perception, but is unlikely to be significant given the reason for the sale.

Key Dates